BridgeBio Pharma, Inc.
BBIO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$68.56
KIRA · Stoqly’s AI analyst, in plain words
- BridgeBio Pharma, Inc. had $502M of revenue in fiscal 2025, up 126.3% on the year before. Over five years, revenue changed +127.4% a year on average.
- Its operating margin was −104.2%, up 163.0 pts: of every 100 in sales, about −104 is left after running the business.
- BridgeBio Pharma, Inc. lost $733M in fiscal 2025.
- Free cash flow was −$447M in fiscal 2025, −89.0% of revenue.
- BridgeBio Pharma, Inc. returned $48.3M to shareholders in fiscal 2025. The diluted share count rose 2.9%.
- BridgeBio Pharma, Inc. owes $1.4B more than it holds in cash.
Market cap
$13.4B
P/E
—
Revenue
$502M
Net income
−$733M
Free cash flow
−$447M
Operating margin
−104.2%
BridgeBio Pharma, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+126.3%
Yes. Sales grew 126.3% last year.
Does it make a profit?
−146.0%
No. It lost money last year.
Does profit turn into cash?
−89.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What BridgeBio Pharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- BridgeBio Pharma, Inc.
- CIK
- 0001743881
BridgeBio Pharma, Inc. · BBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $69.7M | $77.6M | $9.3M | $222M | $502M |
| Revenue growth | 745.1% | 11.4% | −88.0% | 2,285.3% | 126.3% |
| Gross margin | 95.5% | 95.6% | 73.7% | 98.3% | 95.8% |
| Operating margin | −827.1% | −659.6% | −6,528.8% | −267.2% | −104.2% |
| Net income | −$586M | −$485M | −$653M | −$543M | −$733M |
| Net margin | −841.2% | −624.2% | −7,021.9% | −244.9% | −146.0% |
| Diluted EPS | −$3.90 | −$3.26 | −$3.95 | −$2.88 | −$3.78 |
| Cash | |||||
| Cash from operations | −$498M | −$419M | −$528M | −$521M | −$446M |
| Capital expenditure | $13.2M | $4.8M | $1.3M | $0.9M | $1.1M |
| Free cash flow | −$511M | −$424M | −$529M | −$522M | −$447M |
| FCF margin | −733.2% | −546.5% | −5,686.6% | −235.1% | −89.0% |
| Share buybacks | $200M | $0.0M | $0.0M | $0.0M | $48.3M |
| Share count change | 22.3% | 2.2% | 10.4% | 14.3% | 2.9% |
| Debt and strength | |||||
| Cash and short-term investments | $788M | $428M | $376M | $681M | $587M |
| Debt incl. finance leases | $432M | $431M | $446M | $437M | $2.0B |
| Shareholders' equity | −$870M | −$1.3B | −$1.4B | −$1.5B | −$2.1B |
| Current ratio | 6.6x | 4.5x | 3.3x | 4.7x | 2.8x |
| Interest coverage | −12.3x | −6.4x | −7.5x | −6.5x | −9.9x |
| Returns and quality | |||||
| Piotroski F-score | 3 | 3 | 1 | 6 | 2 |
| Altman Z'' | −4.1 | −11.8 | −19.5 | −11.9 | −14.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$115M
10 insiders
Of sales under plans
90%
$103M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
BridgeBio Pharma, Inc. · BBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $68.56 a share, the company is worth $13.4B.
Source: SEC EDGAR XBRL filings (CIK 0001743881). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.